Last reviewed · How we verify

Telik — Portfolio Competitive Intelligence Brief

Telik pipeline: 0 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 2 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
TLK286 HCl for injection TLK286 HCl for injection phase 3 Proteasome inhibitor 20S proteasome Oncology
TLK286 in Combination with Carboplatin TLK286 in Combination with Carboplatin phase 3 Histone deacetylase inhibitor Histone deacetylase Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Chengdu Zenitar Biomedical Technology Co., Ltd · 1 shared drug class
  2. European Myeloma Network B.V. · 1 shared drug class
  3. Evopoint Biosciences Inc. · 1 shared drug class
  4. Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
  5. Medical University of Vienna · 1 shared drug class
  6. Meletios A. Dimopoulos · 1 shared drug class
  7. Merck Sharp & Dohme LLC · 1 shared drug class
  8. Celgene · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Telik:

Cite this brief

Drug Landscape (2026). Telik — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/telik. Accessed 2026-05-13.

Related